| Ledermann, Jonathan A |
| Recruiting | 3 | 330 | Europe, Canada, RoW | Olaparib, Cediranib | University College, London, Cancer Research UK, AstraZeneca UK Limited | Ovarian Cancer | 12/23 | 12/23 | | |
| Active, not recruiting | 2/3 | 504 | Europe | I131 1.1 GBq, Sodium iodide capsule | University College, London, Cancer Research UK | Thyroid Cancer | 12/24 | 03/31 | | |
| Jones, Robert |
DETERMINE, NCT05768178: Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers. |
|
|
| Recruiting | 2/3 | 30 | Europe | Vemurafenib, Zelboraf, Cobimetinib, Cotellic | Cancer Research UK, University of Manchester, University of Birmingham, Royal Marsden NHS Foundation Trust, Hoffmann-La Roche | Solid Tumor, Haematological Malignancy, Melanoma, Thyroid Cancer, Papillary, Ovarian Neoplasms, Colorectal Neoplasms, Laryngeal Neoplasms, Carcinoma, Non-Small-Cell Lung, Glioma, Multiple Myeloma, Erdheim-Chester Disease, Thyroid Carcinoma, Anaplastic | 10/29 | 10/29 | | |
CRUKD/21/004, NCT05722886: DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol |
|
|
| Recruiting | 2/3 | 825 | Europe | Alectinib, Alecensa, Atezolizumab, Tecentriq, Entrectinib, Rozlytrek, Trastuzumab in combination with pertuzumab, Herceptin in combination with Perjeta, Vemurafenib in combination with cobimetinib, Zelboraf in combination with Cotellic | Cancer Research UK, University of Manchester, University of Birmingham, Royal Marsden NHS Foundation Trust, Hoffmann-La Roche | Solid Tumor, Haematological Malignancy | 10/29 | 10/29 | | |
DETERMINE, NCT05786716: Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Teenage/Young Adult and Paediatric Patients With Cancers With HER2 Amplification or Activating Mutations |
|
|
| Recruiting | 2/3 | 30 | Europe | Trastuzumab, Herceptin, Pertuzumab, Perjeta | Cancer Research UK, University of Manchester, University of Birmingham, Royal Marsden NHS Foundation Trust, Hoffmann-La Roche | Solid Tumor, Haematological Malignancy, Colorectal Neoplasms, Urinary Bladder Neoplasm, Gallbladder Neoplasms, Salivary Gland Neoplasm, Lung Neoplasm, Pancreatic Neoplasm, Ovarian Neoplasms, Prostatic Neoplasm, Skin Neoplasm | 10/29 | 10/29 | | |
DETERMINE, NCT05770102: Trial Treatment Arm 02: Atezolizumab in Adult, Teenage/Young Adults and Paediatric Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition |
|
|
| Recruiting | 2/3 | 30 | Europe | Atezolizumab, Tecentriq | Cancer Research UK, University of Manchester, University of Birmingham, Royal Marsden NHS Foundation Trust, Hoffmann-La Roche | Malignancy, Malignant Neoplasm, Lymphoproliferative Disorders, Neoplasms by Histologic Type, Neoplasms by Site, Cancer, Colorectal Neoplasms, Endometrial Neoplasms, Melanoma | 10/29 | 10/29 | | |
DETERMINE, NCT05770037: Trial Treatment Arm 01: Alectinib in Adult, Teenage/Young Adults (TYA) and Paediatric Patients With ALK Positive Cancers |
|
|
| Recruiting | 2/3 | 30 | Europe | Alectinib, Alecensa | Cancer Research UK, University of Manchester, University of Birmingham, Royal Marsden NHS Foundation Trust, Hoffmann-La Roche | Solid Tumor, Haematological Malignancy, Malignant Neoplasm, Lymphoproliferative Disorders, Neoplasms by Histologic Type, Neoplasms by Site, Cancer, Anaplastic Large Cell Lymphoma, Lymphoma, Renal Cell Carcinoma, Neuroblastoma | 10/29 | 10/29 | | |
DETERMINE, NCT05770544: Trial Treatment Arm 03: Entrectinib in Adult, Teenage/Young Adults and Paediatric Patients With ROS1 Gene Fusion-positive Cancers. |
|
|
| Recruiting | 2/3 | 30 | Europe | Entrectinib, Rozlytrek | Cancer Research UK, University of Manchester, University of Birmingham, Royal Marsden NHS Foundation Trust, Hoffmann-La Roche | Solid Tumor, Haematological Malignancy, Malignancy, Malignant Neoplasm, Lymphoproliferative Disorders, Neoplasms by Histologic Type, Neoplasms by Site, Cancer, Brain Neoplasms, Melanoma, Glioma | 10/29 | 10/29 | | |
| Recruiting | 2 | 372 | Europe, Canada, Japan, US, RoW | disitamab vedotin, RC48-ADC, pembrolizumab, KEYTRUDA® | Seagen Inc., Merck Sharp & Dohme LLC | Urothelial Carcinoma | 11/26 | 05/28 | | |
FAKTION, NCT01992952: Fulvestrant +/- Akt Inhibition in Advanced Aromatase Inhibitor Resistant Breast Cancer |
|
|
| Active, not recruiting | 1b/2 | 149 | Europe | AZD5363, Placebo, Fulvestrant | Velindre NHS Trust, AstraZeneca, Cenduit LLC, Covance, Cardiff and Vale University Health Board | Estrogen Receptor Positive Breast Cancer | 03/19 | 12/23 | | |
|
NCT05944237: HTL0039732 in Participants with Advanced Solid Tumours |
|
|
| Recruiting | 1/2 | 150 | Europe | HTL0039732 Capsules, HTL0039732 Capsules and atezolizumab infusion | Cancer Research UK, Nxera Pharma UK Limited | Neoplasms, Prostatic Neoplasms, Castration-Resistant, Stomach Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Colorectal Neoplasms, Pancreatic Neoplasms, Lung Neoplasms, Urinary Bladder Neoplasms, Mesothelioma, Malignant, Uterine Cervical Neoplasms, Kidney Neoplasms, Sarcoma, Pheochromocytomas | 09/26 | 09/26 | | |
NCT04630262: ATTUNE Cementless FB Tibial Base Clinical Study |
|
|
| Terminated | N/A | 80 | US | ATTUNE Cementless CR Fixed Bearing, ATTUNE Cementless PS Fixed Bearing | DePuy Orthopaedics | Osteoarthritis of the Knee | 03/23 | 03/23 | | |
| Active, not recruiting | N/A | 357 | Europe, Canada, US, RoW | Merit WRAPSODY Endovascular Stent Graft, PTA | Merit Medical Systems, Inc. | Venous Stenosis, Venous Occlusion | 02/24 | 01/26 | | |
NCT05527483: Digital PET/CT Using [Ga-68]PSMA vs. [F-18]NaF for Evaluation of Osseous Metastatic Involvement in Prostate Cancer Patients |
|
|
| Completed | N/A | 32 | US | [68Ga]PSMA, Flourine-18 [F-18] Sodium Fluoride (NaF), PET/CT | University Hospitals Cleveland Medical Center | Prostate Cancer | 10/22 | 10/22 | | |
Mossie-GO, NCT06232954: Evaluation of the Protective Efficacy of a Spatial Repellent to Reduce Malaria Prevalence in Uganda |
|
|
| Recruiting | N/A | 5600 | RoW | Mossie-Go containing treated transfluthrin disc, Mossie-Go containing untreated blank disc | Africa Power Limited, Malaria Consortium, ARCTECH INNOVATION LIMITED | Malaria, Mosquito-Borne Disease | 09/25 | 09/25 | | |
NCT04682665: Prebiotic Effect of Eicosapentaenoic Acid Treatment for Colorectal Cancer Liver Metastases |
|
|
| Completed | N/A | 81 | Europe | Icosapent Ethyl Oral Capsule, Placebo | University of Leeds, National Cancer Institute (NCI), Massachusetts General Hospital, Massachusetts Institute of Technology, Harvard School of Public Health (HSPH), University of Bradford | Colon Cancer Liver Metastasis | 07/24 | 07/24 | | |
| Recruiting | N/A | 500 | Europe, RoW | Merit WRAPSODY Endovascular Stent Graft | Merit Medical Systems, Inc. | Venous Stenosis, Venous Occlusion | 12/25 | 07/27 | | |
NCT06797193: Ultrasound with Subharmonic Imaging and Subharmonic Aided Pressure Estimation (SHAPE) to Identify Portal Hypertension |
|
|
| Not yet recruiting | N/A | 60 | US | Electronic Health Record Review, Liver Biopsy, Biopsy of Liver, Medical Device Usage and Evaluation, Perflutren Lipid Microspheres, Definity, Ultrasound Imaging, 2-Dimensional Grayscale Ultrasound Imaging, 2-Dimensional Ultrasound Imaging, 2D-US, Ultrasonography, Ultrasound, Ultrasound Test, Ultrasound, Medical, US | Mayo Clinic | Cirrhosis | 01/27 | 01/27 | | |
| Recruiting | N/A | 6000 | Europe | | The Christie NHS Foundation Trust | Cancer | 01/26 | 01/28 | | |
NCT04907240: Observational GORE® VIABAHN® Endoprosthesis With PROPATEN Bioactive Surface Global Registry |
|
|
| Recruiting | N/A | 614 | Europe | GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface (VSX) | W.L.Gore & Associates | Peripheral Artery Disease, Popliteal Aneurysm, Hemodialysis Access, Visceral Artery Aneurysms, Trauma Injury | 10/26 | 10/35 | | |
ACTRN12619000470190p: FLASH.V: Flash Glucose Monitoring and Surgery in the Hepatopancreaticobiliary (HPB) Surgery and Liver Transplant Population - Verification Study |
|
|
| Not yet recruiting | N/A | 100 | | | University of Melbourne: Department of Surgery , Austin Health Liver Transplant Unit, Austin Medical Research Fund | Liver Transplantation
; Anaesthetics | | | | |
ACTRN12619000470190: FLASH.V: Flash Glucose Monitoring and Surgery in the Hepatopancreaticobiliary (HPB) Surgery and Liver Transplant Population - Verification Study |
|
|
| Not yet recruiting | N/A | 100 | | | University of Melbourne: Department of Surgery , Austin Health Liver Transplant Unit, Austin Medical Research Fund | Liver Transplantation
, Anaesthetics | | | | |
| Recruiting | N/A | 2000 | Europe | Biosampling | University of Liverpool, Countess of Chester NHS Foundation Trust, Liverpool University Hospitals NHS Foundation Trust, Clatterbridge Centre for Oncology, Liverpool Heart and Chest Hospital NHS Foundation Trust, Liverpool Womens Hospital | Cancer, Surgery | 01/30 | 01/30 | | |
| Lee, Siow M |
| Recruiting | 3 | 170 | Europe, Canada, Japan, US, RoW | Selpercatinib, LY3527723, LOXO-292, Placebo | Loxo Oncology, Inc., Eli Lilly and Company | Carcinoma, Non-Small-Cell Lung | 05/27 | 08/32 | | |
| Shaw, Heather S |
| Active, not recruiting | 2 | 271 | Europe | Nivolumab + Ipilimumab, Encorafenib + Binimetinib | European Organisation for Research and Treatment of Cancer - EORTC | Unresectable Stage III Melanoma, Stage IV Melanoma | 10/23 | 01/27 | | |
| Recruiting | 2 | 850 | Europe | Tebentafusp, IMCgp100 | University of Oxford, Immunocore Ltd, Natera, Inc. | Melanoma (Skin), Melanoma, Uveal | 06/25 | 06/26 | | |
| Recruiting | 2 | 130 | Europe | SCIB1 or iSCIB1+ DNA vaccine | Scancell Ltd, Scancell Ltd | Malignant Melanoma, Melanoma (Skin), Melanoma Stage III, Melanoma Stage IV | 01/26 | 01/26 | | |
| Recruiting | 2 | 82 | Europe, Canada, US, RoW | Darovasertib, IDE196, LXS196 | IDEAYA Biosciences | Uveal Melanoma | 01/26 | 01/29 | | |
NCT04785365: Long-Term Follow-Up Study of Patients Receiving ATL001 |
|
|
| Terminated | 2 | 1 | Europe | Biological: ATL001 | Achilles Therapeutics UK Limited | Melanoma, Advanced Non Small Cell Lung Cancer | 10/23 | 10/23 | | |
| Recruiting | 1/2 | 727 | Europe, Canada, US, RoW | Brenetafusp, Brenetafusp and pembrolizumab, Brenetafusp and chemotherapy, Brenetafusp and monoclonal antibodies and chemotherapy, Brenetafusp and tebentafusp, Brenetafusp and bevacizumab, Brenetafusp and kinase inhibitors | Immunocore Ltd | Select Advanced Solid Tumors | 02/26 | 08/26 | | |
|
| Recruiting | 1 | 90 | Europe | NVG-111 | NovalGen Ltd. | Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma, Diffuse Large B Cell Lymphoma, Non-small Cell Lung Cancer (NSCLC), Malignant Melanoma | 12/23 | 12/25 | | |
| Recruiting | N/A | 700 | Europe, Canada, US, RoW | | Columbia University | Uveal Melanoma | 07/26 | 07/26 | | |
| Ardeshna, Kirit |
| Completed | 3 | 462 | Europe, RoW | rituximab, No treatment | University College, London, Cancer Research UK, Roche Pharma AG | Lymphoma | 03/14 | 09/23 | | |
|
|
| Forbes, Alastair |
NCT06164925: Standardising and Simplifying the Global Leadership Initiative on Malnutrition (GLIM) for Its More General Application |
|
|
| Recruiting | N/A | 300 | Europe | Nutrition screening and assessment | University of Tartu, Tartu University Hospital | Malnutrition | 03/24 | 03/25 | | |
| Bridgewater, John A |
| Recruiting | 3 | 800 | Europe | Futibatinib, Ivosidenib, Tibsovo, Zanidatamab, Trastuzumab, Zercepac, Neratinib, Nerlynx, Encorafenib, Braftovi, Binimetinib, Mektovi, Niraparib, Zejula, Cisplatin, Gemcitabine | UNICANCER, Cancer Research UK & UCL Cancer Trials Centre, Belgian Group of Digestive Oncology, National Cancer Institute, France, Cancer Research UK, Taiho Oncology, Inc., Servier, Zymeworks BC Inc., Accord Healthcare, Inc., Pierre Fabre Medicament | Biliary Tract Neoplasms | 06/27 | 06/28 | | |
| Not yet recruiting | 2 | 72 | Europe | Ivonescimab, FOLFOX regimen | UNICANCER, Cancer Research UK & UCL Cancer Trials Centre, Belgian Group of Digestive Oncology, Summit Therapeutics | Biliary Tract Cancer | 08/27 | 01/29 | | |
| Recruiting | 2 | 25 | Europe | Trastuzumab deruxtecan, Enhertu | University of Southampton, AstraZeneca, Natera, Inc. | Gastrooesophageal Cancer | 03/26 | 04/28 | | |
| Recruiting | N/A | 500 | Europe, RoW | Data collection and quality of life questionnaire | Centre Leon Berard | Cancer, Cancer Metastatic, NTRK Gene Fusion Overexpression, NTRK Family Gene Mutation, ATIC-ALK Fusion Protein Expression, ALK Fusion Protein Expression, BCR-FGFR1 Fusion Protein Expression, ROS1 Gene Translocation, COL1A1-PDGFB Fusion Protein Expression, RET Gene Translocation, Gene Fusion, ROS Gene Translocation, BRAF Gene Rearrangement, FGFR2 Gene Translocation, FGFR3 Gene Translocation, NTRK1 Gene Translocation | 06/25 | 06/25 | | |
| Emberton, Mark |
| Recruiting | N/A | 750 | Europe | Biopsy & Imaging | Imperial College London, National Institute for Health Research, United Kingdom | Prostatic Neoplasms | 07/24 | 12/24 | | |
| Active, not recruiting | N/A | 500 | Europe, Canada, US, RoW | Multiparametric MRI +/- prostate biopsy, Biparametric MRI +/- prostate biopsy | University College, London | Prostate Cancer | 12/24 | 03/25 | | |
| Recruiting | N/A | 354 | Europe | questionnaire administration, assessment of therapy complications, high-intensity focused ultrasound ablation, multiparametric magnetic resonance imaging, quality-of-life assessment, transperineal prostate biopsy, transrectal prostate biopsy | University College, London | Male Erectile Disorder, Prostate Cancer, Therapy-related Toxicity, Urinary Incontinence | 12/28 | 06/29 | | |
| McCormack, Mary |
| Active, not recruiting | 3 | 500 | Europe, RoW | Paclitaxel, Carboplatin, Radiotherapy, Cisplatin | University College, London, Cancer Research UK | Cervical Cancer | 02/26 | 12/26 | | |
NCT04081714: Intermediate Expanded Access Protocol CNMAu8.EAP03 |
|
|
| Available | N/A | | US | CNM-Au8, Nanocrystalline gold | Clene Nanomedicine, University of Texas, Southwestern Medical Center at Dallas | Multiple Sclerosis | | | | |
| Available | N/A | | US | CNM-Au8, Nanocrystalline gold | Clene Nanomedicine | Amyotrophic Lateral Sclerosis | | | | |
| Chataway, Jeremy |
| Completed | 3 | 964 | Europe | Simvastatin, Placebo | University College, London, University of Edinburgh, Queen Mary University of London, London School of Hygiene and Tropical Medicine, University of Leeds, The Leeds Teaching Hospitals NHS Trust, Imperial College Healthcare NHS Trust | Secondary Progressive Multiple Sclerosis (SPMS) | 07/24 | 08/24 | | |
| Roylance, Rebecca |
| Active, not recruiting | 3 | 654 | Europe, Canada, Japan, US, RoW | Tucatinib, TUKYSA, ONT-380, ARRY-380, Trastuzumab, Herceptin, Herceptin Hylecta, Pertuzumab, Perjeta, Combination product: Trastuzumab + Pertuzumab, Phesgo, Placebo | Seagen Inc., Merck Sharp & Dohme LLC | HER2 Positive Breast Cancer | 05/25 | 10/27 | | |
|
PARTNER, NCT03150576: Platinum and Polyadenosine 5'Diphosphoribose Polymerisation Inhibitor for Neoadjuvant Treatment of Triple Negative Breast Cancer and/or Germline BRCA Positive Breast Cancer |
|
|
| Recruiting | 2/3 | 780 | Europe | Olaparib, Lynparza, Paclitaxel and Carboplatin, Taxol and Paraplatin | Cambridge University Hospitals NHS Foundation Trust, AstraZeneca, Cancer Research UK | Breast Cancer | 06/24 | 06/34 | | |
| Active, not recruiting | 2 | 58 | Europe | Crizotinib Oral Capsule [Xalkori], Xalkori, Fulvestrant 50 MG/ML Prefilled Syringe [Faslodex or generic], Faslodex | Royal Marsden NHS Foundation Trust, Pfizer, Breast Cancer Now | Lobular Breast Carcinoma, Gastric Cancer, Triple Negative Breast Cancer, CDH1 Gene Mutation | 07/24 | 07/24 | | |
FAIM, NCT04920708: Fulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression |
|
|
| Recruiting | 2 | 324 | Europe | Ipatasertib 300mg, RG7440, Fulvestrant 500g, Faslodex, Palbociclib 75mg-125mg, Ibrance, CDK4/6 Inhibitor, Abemaciclib / Ribociclib / Palbociclib | Royal Marsden NHS Foundation Trust, Pfizer, Hoffmann-La Roche | Metastatic Breast Cancer, ER+ Breast Cancer, Advanced Breast Cancer | 09/26 | 09/26 | | |
TRAK-ER, NCT04985266 / 2020-004022-36: A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer |
|
|
| Recruiting | 2 | 1100 | Europe | Palbociclib 125Mg Tab, Fulvestrant injection, Tamoxifen, Letrozole, Exemestane, Anastrozole | Royal Marsden NHS Foundation Trust, Pfizer, AstraZeneca, Institute of Cancer Research, United Kingdom, UNICANCER, Gustave Roussy, Cancer Campus, Grand Paris, Invitae Corporation | ER+ Breast Cancer, HER2-negative Breast Cancer | 09/27 | 09/30 | | |
ELEVATE, NCT05563220: Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer |
|
|
| Recruiting | 1/2 | 400 | Europe, US, RoW | Elacestrant, Alpelisib, Piqray, Everolimus, Afinitor, Ribociclib, Kisqali, Palbociclib, Ibrance, Capivasertib, Truqap, Abemaciclib, Verzenio | Stemline Therapeutics, Inc. | Breast Cancer, Metastatic Breast Cancer | 12/24 | 08/26 | | |
| Recruiting | 1 | 45 | Europe | Palbociclib, Ibrance, Avelumab, Bavencio | Royal Marsden NHS Foundation Trust, Pfizer, Breast Cancer Now | Triple Negative Breast Cancer, Locally Advanced Breast Cancer, Recurrent Breast Cancer, Metastatic Breast Cancer, ER+ Breast Cancer, HER2-positive Breast Cancer | 07/25 | 12/25 | | |
| Emmanuel, Anton |
NCT04707976: Comparing Transanal Irrigation With Navina Smart vs. Standard Bowel Care in Patients With Multiple Sclerosis |
|
|
| Recruiting | N/A | 92 | Europe | Navina Smart, Standard Bowel Care | Wellspect HealthCare, Wellspect HealthCare | Neurogenic Bowel (Disorder), Fecal Constipation, Fecal Incontinence, Multiple Sclerosis | 12/24 | 02/25 | | |
| DeSantes, Kenneth |
PINES, NCT03939637: Eltrombopag Vs Standard Front Line Management for Newly Diagnosed Immune Thrombocytopenia (ITP) in Children |
|
|
| Active, not recruiting | 3 | 122 | US | Eltrombopag, Steroids, IVIG, Rho(D) Immune Globulin | Baylor College of Medicine, Boston Children's Hospital, University of California, San Francisco | Immune Thrombocytopenia | 03/25 | 12/25 | | |
TransIT, NCT05600426: A Trial Comparing Unrelated Donor BMT with IST for Pediatric and Young Adult Patients with Severe Aplastic Anemia (, BMT CTN 2202) |
|
|
| Recruiting | 3 | 234 | Canada, US | cyclosporine, Matched Unrelated Donor Hematopoetic Stem Cell Transplant, horse anti-thymocyte globulin (ATG), ATGAM, rabbit anti-thymocyte globulin (ATG), thymoglobulin, Methotrexate, Fludarabine, Cyclophosphamide, low-dose total body irradiation (TBI), Immunosuppressive Therapy (IST) | Boston Children's Hospital, Center for International Blood and Marrow Transplant Research, National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), North American Pediatric Aplastic Anemia Consortium, Pediatric Transplantation and Cellular Therapy Consortium, Blood and Marrow Transplant Clinical Trials Network | Severe Aplastic Anemia | 12/29 | 12/29 | | |
OPTIMUM, NCT03561259: A Study of Therapeutic Iobenguane (131-I) and Vorinostat for Recurrent or Progressive High-Risk Neuroblastoma Subjects |
|
|
| Recruiting | 2 | 60 | US | 131I-MIBG, I-131 meta-iodobenzylguanidine, Iobenguane I-131 MIBG Injection, 131-MIBG + Vorinostat | Jubilant DraxImage Inc. | Neuroblastoma, Neuroectodermal Tumors, Neoplasms | 12/23 | 04/25 | | |
NCT01656603: Safety Study of Unlicensed IND Cord Blood Units Manufactured by the National Cord Blood Program for Unrelated Transplantation |
|
|
| Recruiting | 2 | 9999 | US | unlicensed CBU | New York Blood Center | Infusion Reactions | 12/25 | 12/25 | | |
| Recruiting | 2 | 64 | Canada, US | Busulfan, Cell processing for TCRαβ+/CD19+ depletion, CliniMACS | Michael Pulsipher, MD | SCID | 08/26 | 08/26 | | |
NCT04023331: 67Cu-SARTATE™ Peptide Receptor Radionuclide Therapy Administered to Pediatric Patients With High-Risk, Relapsed, Refractory Neuroblastoma |
|
|
| Recruiting | 1/2 | 34 | US | 67Cu-SARTATE, Cu-67 SARTATE, copper 67 SARTATE, 64Cu-SARTATE, Cu-64 SARTATE, copper 64 SARTATE | Clarity Pharmaceuticals Ltd | Neuroblastoma, Relapsed Neuroblastoma, Refractory Neuroblastoma | 12/28 | 12/28 | | |
| Active, not recruiting | 1 | 44 | Europe, US | Nivolumab, BMS-936558, MDX1106, ONO-4538, anti-PD-1) NSC#748726, IND #124729, Ch14.18/CHO, Mouse-human chimeric monoclonal anti-GD2 Immunoglobulin G1 (IgG1) antibody | University Hospital Southampton NHS Foundation Trust, University College London Hospitals, University of Wisconsin, Madison, University Hospital Greifswald, Solving Kids' Cancer US/EU, Joining Against Cancer in Kids, The Band of Parents | Neuroblastoma | 05/25 | 07/25 | | |
NCT03798301: Treatment of Cytomegalovirus (CMV) Infections With Viral-Specific T Cells |
|
|
| Terminated | 1 | 3 | US | CMV-specific T-cells | University of Wisconsin, Madison, University of Wisconsin Carbone Cancer Center (UWCCC) | CMV Infection, Cytomegalovirus Infections, CMV Viremia, Opportunistic Infections | 05/23 | 05/23 | | |
NCT04806347: Alpha/Beta T-cell Depleted Blood-forming Stem Cell Transplant From Related or Unrelated Donors for Blood Diseases in Children and Young Adults |
|
|
| Not yet recruiting | 1 | 12 | NA | TCRαβ+/CD19+ depleted Hematopoietic stem cell (HSC) graft, CliniMACS® System | University of Wisconsin, Madison, University of Wisconsin Carbone Cancer Center (UWCCC) | Blood Disease | 07/28 | 07/29 | | |
NCT01351545: A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) |
|
|
| Recruiting | N/A | 99999 | US | A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) | Center for International Blood and Marrow Transplant Research, National Marrow Donor Program | Hematologic Malignancies, Inherited Disorders of Metabolism, Inherited Abnormalities of Platelets, Histiocytic Disorders, Acute Myelogenous Leukemia (AML or ANLL), Acute Lymphoblastic Leukemia (ALL), Other Acute Leukemia, Chronic Myelogenous Leukemia (CML), Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases, Other Leukemia, Hodgkin Lymphoma, Non-hodgkin Lymphoma, Multiple Myeloma/ Plasma Cell Disorder (PCD), Inherited Abnormalities of Erythrocyte Differentiation or Function, Disorders of the Immune System, Autoimmune Diseases, Severe Aplastic Anemia | 10/41 | 10/41 | | |
| Janes, Sam |
| Recruiting | 1/2 | 46 | Europe | MSCTRAIL, Mesenchymal stromal cells genetically modified to express TRAIL, Placebo | University College, London | Adenocarcinoma of Lung | 09/23 | 09/25 | | |
| Recruiting | N/A | 526 | Europe | | University College, London | Lung Cancer | 08/25 | 03/26 | | |
| Navani, Neal |
| Recruiting | N/A | 1000 | Europe | Machine Learning Classification | Royal Marsden NHS Foundation Trust, RM Partners West London Cancer Alliance, Royal Brompton & Harefield NHS Foundation Trust, University College London Hospitals, Imperial College Healthcare NHS Trust, Lewisham and Greenwich NHS Trust, King's College Hospital NHS Trust, Epsom and St Helier University Hospitals NHS Trust, Institute of Cancer Research, United Kingdom, Guy's and St Thomas' NHS Foundation Trust, UCLH Biomedical Research Centre | Lung Cancer, Pulmonary Nodule, Multiple, Pulmonary Nodule, Solitary, Lung Neoplasms | 08/21 | 08/21 | | |
| Recruiting | N/A | 500 | Europe | | Royal Marsden NHS Foundation Trust, Royal Brompton & Harefield NHS Foundation Trust, Royal Marsden Partners West London Cancer Alliance, Imperial College London, University College London Hospitals, Lewisham and Greenwich NHS Trust, Guy's and St Thomas' NHS Foundation Trust, Epsom and St Helier University Hospitals NHS Trust, King's College Hospital NHS Trust, University College London (UCL) Cancer Institute, Institute of Cancer Research, United Kingdom, Francis Crick Institute, Royal Sussex County Hospital | Lung Cancer | 01/26 | 01/31 | | |
| Peggs, Karl |
NCT02893189: CAR19 Donor Lymphocytes for Relapsed CD19+ Malignancies Following Allogeneic Transplantation |
|
|
| Completed | 1 | 17 | Europe | Infusion of modified CAR19 T-cells (4G7-CARD T-cells) | University College, London | CD19+ Malignancies: Relapse Post-allogeneic Transplant | 12/19 | 12/22 | | |
ALLCAR19, NCT02935257: Immunotherapy for High Risk/Relapsed CD19+ Acute Lymphoblastic Leukaemia, B-cell Non-Hodgkin's Lymphoma (B-NHL) and Chronic Lymphocytic Leukaemia (CLL)/ Small Lymphocytic Lymphoma (SLL) Using CAR T-cells to Target CD19 |
|
|
| Recruiting | 1 | 60 | Europe | CD19CAT-41BBZ CAR T-cells | University College, London | Leukemia, Lymphoblastic, Acute, Lymphoma | 12/24 | 12/33 | | |
| Recruiting | N/A | 150 | Europe, RoW | No Intervention | Takeda | Cytomegalovirus (CMV) | 04/25 | 04/25 | | |
| Investigator, Principal |
| Completed | 4 | 144 | Europe | Opicapone 50 mg, BIA 9-1067, Placebo | Bial - Portela C S.A., Bial - Portela & Ca, S.A. | Parkinson Disease | 02/24 | 02/24 | | |
NCT04248205: Ketamine for Post-operative Analgesia in Hemorrhoidectomy |
|
|
| Recruiting | 4 | 100 | US | Ketamine | University of Oklahoma | Hemorrhoids | 01/25 | 07/25 | | |
NCT05400369: A Study to Evaluate the Efficacy and Safety of Sitafloxacin in Adult Subjects With Acute Exacerbation of Chronic Obstructive Pulmonary Disease |
|
|
| Completed | 4 | 140 | RoW | Sitafloxacin, Gracevit, Moxifloxacin Hydrochloride, Avelox | Daiichi Sankyo | COPD Exacerbation Acute | 09/24 | 09/24 | | |
TrEAT_TD2, NCT05677282: Single Dose Antibiotic Treatment of Acute Watery Diarrhea, Rifaximin Versus Azithromycin, with Loperamide Adjunct |
|
|
| Recruiting | 4 | 150 | RoW | Rifaximin 550 MG, Azithromycin 500 MG, Loperamide | Henry M. Jackson Foundation for the Advancement of Military Medicine, Infectious Diseases Clinical Research Program, Uniformed Services University of the Health Sciences | Diarrhoea;Acute, Diarrhea Travelers | 09/25 | 12/25 | | |
NCT06397781: Effect of S. Aureus Skin Decolonization on Disease Severity in Atopic Dermatitis Patients |
|
|
| Not yet recruiting | 4 | 100 | US | Skin Cleanser Combination No.1 | Boston Children's Hospital | Atopic Dermatitis | 12/28 | 12/28 | | |
NCT06793358: Use of Remimazolam and Fentanyl for Procedural Sedation in Patients Undergoing Dental Extraction |
|
|
| Not yet recruiting | 4 | 40 | US | fentanyl and Remimazolam | Indiana University, Indiana University Health | Dental Extraction | 01/26 | 03/26 | | |
POUR, NCT04994431: Post-Operative Urinary Retention () in Thoracic Surgery Patients Receiving Prophylactic Tamsulosin |
|
|
| Terminated | 4 | 109 | US | Tamsulosin Hydrochloride | University of Massachusetts, Worcester, UMass Memorial Health Care | Thoracic Diseases, Urinary Retention | 10/23 | 10/23 | | |
NCT02932410 / 2016-001062-28: A Study to Assess Whether Macitentan Delays Disease Progression in Children With Pulmonary Arterial Hypertension (PAH) |
|
|
| Active, not recruiting | 3 | 165 | Europe, Canada, US, RoW | Macitentan, ACT-064992, Standard-of-care | Actelion | Pulmonary Arterial Hypertension | 08/24 | 07/25 | | |
| Active, not recruiting | 3 | 590 | Europe, Canada, Japan, US, RoW | DS-1062a, Datopotamab deruxtecan (Dato-DXd), Docetaxel | Daiichi Sankyo, AstraZeneca | Non-small Cell Lung Cancer | 05/24 | 06/25 | | |
|
|
IDeate-Lung02, NCT06203210: A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer |
|
|
| Recruiting | 3 | 540 | Europe, Canada, Japan, US, RoW | Ifinatamab deruxtecan, I-DXd, Topotecan, Amrubicin, Lurbinectedin | Daiichi Sankyo, Merck Sharp & Dohme LLC | Small Cell Lung Cancer | 04/27 | 02/29 | | |
TNX-N, NCT03503136: Nedaplatin Versus Cisplatin and Capecitabine Versus Fluorouracil in IC + CCRT for Locoregionally Advanced NPC |
|
|
| Not yet recruiting | 3 | 632 | RoW | docetaxel, nedaplatin, and capecitabine, TNX induction chemotherapy, nedaplatin, N, docetaxel, cisplatin, and fluorouracil, TPF induction chemotherapy, cisplatin, P, docetaxel, cisplatin, and capecitabine, TPX induction chemotherapy, docetaxel, nedaplatin, and fluorouracil, TNF induction chemotherapy | Sun Yat-sen University, Tongji Hospital, Wuhan Union Hospital, China, Peking University, Air Force Military Medical University, China, Second Affiliated Hospital of Soochow University, The First Affiliated Hospital of Guangdong Pharmaceutical University, First People's Hospital of Foshan, Fifth Affiliated Hospital, Sun Yat-Sen University, Cancer Hospital of Guizhou Province, Xiangya Hospital of Central South University, Jilin Provincial Tumor Hospital, Henan Cancer Hospital, Hunan Cancer Hospital, Cancer Hospital of Guangxi Medical University, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Zhejiang Cancer Hospital | Nasopharyngeal Carcinoma | 06/24 | 06/26 | | |
NCT05839899: Mifepristone and Misoprostol for Undesired Pregnancy of Unknown Location |
|
|
| Recruiting | 3 | 50 | US | Mifepristone plus one dose Misoprostol, Mifepristone plus two doses Misoprostol | Planned Parenthood League of Massachusetts | Abortion | 07/24 | 09/24 | | |
| Active, not recruiting | 3 | 586 | Europe, Canada, Japan, US, RoW | Patritumab Deruxtecan, HER3-DXd, U3-1402, Platinum-based chemotherapy | Daiichi Sankyo, Merck Sharp & Dohme LLC | Nonsquamous Non-small Cell Lung Cancer, EGFR L858R, EGFR Exon 19 Deletion | 05/24 | 06/26 | | |
CYPRESS, NCT05696717: Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic NOH in Participants with Multiple System Atrophy |
|
|
| Recruiting | 3 | 102 | Europe, Canada, US, RoW | Ampreloxetine, TD-9855, Placebo | Theravance Biopharma | Symptomatic Neurogenic Orthostatic Hypotension, MSA - Multiple System Atrophy | 12/24 | 01/27 | | |
| Not yet recruiting | 3 | 615 | RoW | Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection | Beijing VDJBio Co., LTD. | Rheumatoid Arthritis (RA) | 12/25 | 12/26 | | |
LIBERTY, NCT06716814: Study to Provide Continued Access to Treatment for Patients Completing a Previous Trial With Efanesoctocog Alfa |
|
|
| Not yet recruiting | 3 | 78 | Europe | Efanesoctocog alfa, BIVV001, Altuvoct, Altuviiio, Recombinant coagulation factor VIII Fc-von-Willebrand Factor-XTEN fusion protein (rFVIIIFc-VWF-XTEN) | Swedish Orphan Biovitrum, PSI CRO | Severe Haemophilia A | 08/26 | 08/26 | | |
NCT06672016: Study to Evaluate Contraceptive Efficacy and Safety of a Progestin Only Patch in Women of Childbearing Potential |
|
|
| Recruiting | 3 | 1500 | US | Transdermal system containing progestin | Mylan Pharmaceuticals Inc | Female Contraception | 03/27 | 04/27 | | |
| Active, not recruiting | 3 | 899 | Europe, Canada, Japan, US, RoW | Tafasitamab, Monjuvi, Lenalidomide, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Tafasitamab placebo, Lenalidomide placebo | Incyte Corporation | Diffuse Large B-cell Lymphoma | 06/25 | 05/26 | | |
|
|
|
| Completed | 3 | 1 | US | StrataGraft | Stratatech, a Mallinckrodt Company, Biomedical Advanced Research and Development Authority | Skin Wound, Burns, Trauma-related Wound | 05/24 | 05/24 | | |
| Active, not recruiting | 3 | 490 | Europe, Japan, RoW | Trastuzumab deruxtecan, T-DXd, DS-8201a, ENHERTU®, Ramucirumab, CYRAMZA®, Paclitaxel | Daiichi Sankyo, AstraZeneca | Gastric Cancer, Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | 10/25 | 02/26 | | |
|
|
|
|
NCT05847348: 68Ga-PSMA-11 Efficacy in Detecting BCR Prostate Cancer in Chinese Patients |
|
|
| Recruiting | 3 | 110 | RoW | 68Ga-PSMA-11, Illucix, gallium Ga 68 Gozetotide, PET/CT or PET/MRI, Imaging by PET | Telix Pharmaceuticals (Innovations) Pty Limited, Grand Pharmaceutical (China) Co., Ltd. | Biochemical Recurrence of Malignant Neoplasm of Prostate, Prostate Cancer, BCR Prostate Carcinoma | 12/25 | 07/26 | | |
| Active, not recruiting | 3 | 1600 | Europe, Canada, Japan, US, RoW | DS-8201a, Trastuzumab deruxtecan (T-DXd), T-DM1, Trastuzumab emtansine (T-DM1) | Daiichi Sankyo, AstraZeneca, NSABP Foundation Inc, German Breast Group, Spanish Breast Cancer Research Group (SOLTI) | HER2-Positive Primary Breast Cancer, Residual Invasive Breast Cancer | 12/25 | 12/30 | | |
|
|
FREEDOM, NCT05817812: A Study Evaluating Physical Activity and Joint Health in Severe Haemophilia A Patients ≥12 Years Treated Once Weekly With Efanesoctocog Alfa |
|
|
| Active, not recruiting | 3 | 93 | Europe, RoW | Efanesoctocog alfa, BIVV001 | Swedish Orphan Biovitrum, Syneos Health | Hemophilia A, Severe | 05/26 | 05/26 | | |
TROPION-Lung07, NCT05555732: Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer |
|
|
| Recruiting | 3 | 1170 | Europe, Canada, Japan, US, RoW | Datopotamab Deruxtecan, Dato-DXd, Pembrolizumab, KEYTRUDA®, Pemetrexed, Alimta, Pemfexy, Carboplatin, Cisplatin | Daiichi Sankyo, AstraZeneca, Merck Sharp & Dohme LLC | Metastatic Non Small Cell Lung Cancer | 08/27 | 08/27 | | |
DESTINY-Breast15, NCT05950945: Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer |
|
|
| Recruiting | 3 | 250 | Europe, US, RoW | Trastuzumab Deruxtecan, T-DXd, DS-8201a (trastuzumab derextecan), Enhertu® | Daiichi Sankyo, AstraZeneca | Breast Cancer | 10/27 | 10/27 | | |
| Recruiting | 3 | 740 | Europe, Canada, Japan, US, RoW | Datopotamab Deruxtecan, Dato-DXd, Pembrolizumab, KEYTRUDA® | Daiichi Sankyo, AstraZeneca, Merck Sharp & Dohme LLC | Metastatic Non Small Cell Lung Cancer | 02/28 | 04/28 | | |
|
|
ARTEMIS, NCT04797884: Electromagnetic Fields Versus Placebo For Child-Pugh A and B Patients With Advanced Hepatocellular Carcinoma |
|
|
| Recruiting | 2/3 | 166 | US | TheraBionic Device, Placebo Device, Quality of Life Assessment | THERABIONIC INC., National Cancer Institute (NCI) | Hepatocellular Carcinoma | 10/24 | 10/24 | | |
FORTIFI-HN01, NCT06788990: a Study of Ficerafusp Alfa (BCA101) or Placebo in Combination with Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC |
|
|
| Recruiting | 2/3 | 650 | US | Ficerafusp alfa, Pembrolizumab (KEYTRUDA®), Placebo | Bicara Therapeutics | Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma | 04/28 | 07/29 | | |
TRIPHASE, NCT06101745: Trial to Visualize the Ureters With Nizaracianine Triflutate in Adults Undergoing Abdominopelvic Surgery |
|
|
| Recruiting | 2/3 | 336 | Europe | Nizaracianine Triflutate, ZW800-1, Placebo Comparator, Sugar | Curadel Surgical Innovations, Inc., Leiden University Medical Center, Erasmus Medical Center | Injury of Ureter During Surgery (Disorder) | 10/25 | 11/25 | | |
| Terminated | 2 | 16 | Europe, Canada, US, RoW | Belcesiran, Placebo | Dicerna Pharmaceuticals, Inc., a Novo Nordisk company | Alpha 1-Antitrypsin Deficiency | 12/23 | 05/24 | | |
